This is a sham-controlled, randomized trial for patients with MDD to identify the effects of TBS on depressive symptomatology, brain function, and peripheral biomarkers in MDD patients.
This is a sham-controlled, randomized trial for patients with MDD to identify the effects of TBS on depressive symptomatology, brain function (e.g. functional MRI, PET, and qEEG), peripheral biomarkers (e.g. candidate genetic expression, neuroendocrine, inflammation, and neurotransmissions) in MDD patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
80
Hamilton Rating Scale for Depression (HAMD)
The Hamilton Depression scale sum score (HAMD21) * Not depressed: 0-7 * Mild: 8-13 * Moderate: 14-18 * Severe: 19-22 * Very severe: \>23
Time frame: From Weeks 0 to 24
Response rate
The decreasing level of the Hamilton Rating Scale for Depression from 0% to 50% compared to the sham group.
Time frame: From Weeks 0 to 24
Remission rate
The higher scores on the Hamilton Rating Scale for Depression down to 8 points would be considered remission.
Time frame: From Weeks 0 to 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.